MENU
Go to the list of all blogs
Vitalii Liubimov's Avatar
published in Blogs
Jun 22, 2020

Mixed Messages on Biotech Sector with Strong Fundamentals, but Overvalued Currently

The current health crisis has created a lot of buzz around the biotech sector as several companies from the sector are working on potential vaccines against the COVID-19 virus. That buzz has created somewhat of a mixed message for the sector as a whole. Many of the companies are overvalued at this time, but the fundamentals of many are really good.

I looked at the SPDR S&P Biotech ETF (NYSE: XBI) and its components. First, I looked at the chart of the ETF itself and saw the huge bounce off of the March low—moving from the $65 area to over $110 in approximately three months. As impressive as the move is, it is also troubling for someone like me that has a hard time buying stocks or ETFs when they are overbought.

After looking at the chart and the move the XBI has made, I started looking at the individual companies and their fundamental ratings along with the scorecard grades from Tickeron. What I found there was pretty impressive.

Of the 85 components in the XBI, 41 are rated as a “strong buy” and 17 are rated as a “buy”. There are seven “hold” ratings, eight “sell” ratings, and 10 “strong sell” ratings. There were also two that didn’t have a rating on the scorecard. I found it to be a really good sign for the long-term prospects of the sector with almost 70% of the ratings coming in at a buy or better. Keep in mind these ratings are strictly based on artificial intelligence, they aren’t the same thing as analysts’ ratings where human opinions are taken in to account.

The problem with the components is that so many are overvalued at this time. Of the 85 stocks in the fund, 45 are “overvalued”, 29 are “fairly valued”, and only 11 are “undervalued”.

The biotechnology industry involves genetic or protein engineering. The goal is to produce medicines or therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion dollar industry is heavily focused on research and development.  Companies are continuously attempting to come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide growth opportunities for the companies. However, discoveries must pass regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets.

Some of the most notable companies in the group are Amgen Inc. (NASDAQ:AMGN), Gilead Sciences, Inc. (NASDAQ:GILD), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Illumina Inc (NASDAQ:ILMN), Biogen Inc (NASDAQ:BIIB), Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Moderna Inc (NASDAQ:MRNA), Incyte Corp. (NASDAQ:INCY), Exact Sciences Corp. (NASDAQ:EXAS), and Sarepta Therapeutics Inc (NASDAQ:SRPT).

Of those notable companies, only Amgen falls in to the undervalued category at this time. Exact Sciences is fairly valued and all the rest of those notable companies are in the overvalued category at this time.

What all of this suggest to me is that the long-term prospects for the XBI and the biotech sector as a whole are really good. But investors might want to wait for a pullback before jumping in.

One particular technical indicator that jumped out at me was the RSI indicator. Over the last three weeks or so, 36 of the stocks in the XBI have received a signal from this indicator and only four of those 36 were bullish signals with good odds of success. There was one bearish signal that didn’t have good odds of success, but there were 31 bearish signals where the odds of success were at 60% or better. 

Given all of this information, I can see making a bullish trade on the biotech sector if the stocks as a whole see a little pullback. If enough of the stocks go through a little downturn, it should reduce the number of stocks that are overvalued. Such a move would give investors a chance to enter a trade without buying when the indicators are in overbought territory.

Related Ticker: XBI

XBI's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Oscillator for XBI moved out of overbought territory on June 11, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 instances where the indicator moved out of the overbought zone. In of the 20 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 20, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on XBI as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for XBI turned negative on June 20, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

XBI broke above its upper Bollinger Band on June 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

XBI moved above its 50-day moving average on June 02, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for XBI crossed bullishly above the 50-day moving average on May 30, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 206 cases where XBI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Notable companies

The most notable companies in this group are ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exact Sciences Corp (NASDAQ:EXAS), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").

Market Cap

The average market capitalization across the SPDR® S&P Biotech ETF ETF is 7.86B. The market cap for tickers in the group ranges from 120.07M to 322.43B. ABBV holds the highest valuation in this group at 322.43B. The lowest valued company is EBS at 120.07M.

High and low price notable news

The average weekly price growth across all stocks in the SPDR® S&P Biotech ETF ETF was -1%. For the same ETF, the average monthly price growth was 4%, and the average quarterly price growth was -10%. VERV experienced the highest price growth at 80%, while SRPT experienced the biggest fall at -44%.

Volume

The average weekly volume growth across all stocks in the SPDR® S&P Biotech ETF ETF was 53%. For the same stocks of the ETF, the average monthly volume growth was 45% and the average quarterly volume growth was -30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 78
Price Growth Rating: 59
SMR Rating: 87
Profit Risk Rating: 86
Seasonality Score: 27 (-100 ... +100)
View a ticker or compare two or three
XBI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
SPDR Series TrustOne Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com
Interact to see
Advertisement
Paper wallets are extremely useful tools – beyond being one of the most popular and secure cold storage methods, they make it simple to transfer coins between owners.You can access the funds on your paper wallet by “sweeping” (or importing) them to either a live wallet (like Trezor or Exodus) or an exchange service (like Coinbase). Most services allow you to import them directly from your wallet’s private key, but there are two key exceptions.
Learn the 27 essential intraday trading rules that every manual trader should master—and discover how Tickeron’s AI platform applies them automatically for consistent, emotion-free execution and smarter, real-time decision-making.
#investment#trading
A $2 trillion sell-off has investors asking: is 2025 the next dot-com crash or a replay of the 2008 recession? This deep dive compares both scenarios, outlines warning signs, and reveals how AI-powered trading strategies can help navigate rising volatility.
#trading#investment
New to trading? Discover 21 powerful lessons every beginner must learn—and see how Tickeron’s AI Double Agent strategies apply them in real time. From mastering risk to managing emotions, this guide helps you trade smarter, safer, and more confidently.
#investment#trading
From the railroads of the 1920s to the AI giants of 2025, market history shows that extreme concentration often precedes massive bubbles and crashes. This article explores five key turning points and how Tickeron’s AI helps traders navigate today’s bubble-prone landscape.
#investment#trading
U.S. tariff tensions rocked markets this week, sending tech stocks into retreat and safe-haven assets like gold and the yen soaring. As investors brace for major earnings and global policy shifts, volatility remains high across equities, currencies, and commodities.
#investment#trading
Tesla’s Q1 2025 earnings could surprise investors as the EV giant looks to rebound from last quarter’s miss. With lowered expectations and increased volatility, Tickeron’s AI-powered strategy helps traders navigate both upside potential and downside risk.
#investment#trading
Gold is on a historic run—up 29% YTD with record-breaking inflows and growing macro tailwinds. Discover why smart investors are eyeing gold, silver, and miners for opportunity, and how AI trading tools are unlocking new ways to profit from the 2025 gold rush.
#investment#trading
Tickeron launches its innovative Double Agent Trading Bot, combining long NVDA trades with hedged NVDS positions. Using AI-driven pattern trading and real-time risk management, the bot achieves a 75% success rate, revolutionizing automated trading strategies.
#trading#investment
Tickeron’s AI trading bots are setting new standards in finance, achieving up to 86.6% win rates across leveraged and sector ETFs. Powered by advanced Financial Learning Models (FLMs), Tickeron’s AI delivers precision, adaptability, and real-time trading success.
#trading
Wall Street expects strong profit growth from the Magnificent Seven tech giants in 2025. Discover how to trade Apple, Microsoft, Amazon, Nvidia, Tesla, Meta, and Alphabet using AI-powered Double Agent strategies and smart hedging with inverse ETFs like QID.
On May 2, 2025, a diverse group of companies across energy, financial services, basic materials, consumer discretionary, and healthcare will release their Q1 2025 earnings.
In April 2025, five tech giants—NVIDIA, Tesla, Meta, Palantir, and Amazon—each surged over 40%, driven by AI breakthroughs, strong earnings, and market momentum. Discover what fueled the rally and how Tickeron’s AI trading bots helped investors outperform even these star stocks.
#investment
Markets ended April with mixed signals—gold slid on trade optimism, Big Tech lifted the Nasdaq, and Bitcoin steadied near $94K. With U.S. GDP contracting and job growth beating forecasts, investors brace for more volatility amid tariffs and central bank moves.
In a turbulent market, Tickeron's AI-powered Double Agent Bot is outperforming traditional strategies. Leveraging real-time intraday signals and inverse ETFs, the bot posted a +9.77% quarterly gain while the S&P 500 dropped 9.28%. Here's how AI is reshaping trading.
#trading
As Warren Buffett announces his retirement, investors turn to his trusted Buffett Indicator—a ratio of market cap to GDP—as a key gauge of market valuation.
#investment
Markets move in repeating cycles—Accumulation, Uptrend, Distribution, and Downtrend. Learn how to recognize each phase and deploy Tickeron’s AI-powered Double Agent strategy to adapt, protect capital, and profit in any market condition.
#trading
Discover how confirmation trading techniques—like moving average crossovers and volume-backed breakouts—can improve accuracy and reduce false signals. Learn how Tickeron’s AI automates these strategies for smarter, faster, and more disciplined trading.
#trading
Hedge funds are ramping up bearish bets on small-cap stocks, with Russell 2000 short interest hitting new highs. As macro headwinds mount and technical support teeters, Tickeron’s AI Double Agents step in to navigate the looming sell-off with precision.
#investment#trading#artificial_intelligence
SPY’s Momentum Indicator turned bullish on April 25, 2025, signaling a potential trend shift with a 90% historical success rate. This article explores how economic scarcity, technical signals, and AI-driven tools like Tickeron’s A.I.dvisor shape investor decisions in volatile markets.
#trading